 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | Journal: Comparison table: Some drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available
- || Review, Journal: Drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available No abstract available
- || levodopa/carbidopa ER (WD-1603) / China NT Pharma
New P1 trial: Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions (clinicaltrials.gov) - Nov 18, 2021
P1, N=15, Recruiting, Sponsor: Shanghai WD Pharmaceutical Co., Ltd.
- || levodopa/carbidopa ER (WD-1603) / China NT Pharma
Enrollment open: A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease (clinicaltrials.gov) - Oct 31, 2021
P2, N=40, Recruiting, Sponsor: Shanghai WD Pharmaceutical Co., Ltd.
No abstract available Not yet recruiting --> Recruiting
- | levodopa/carbidopa ER (WD-1603) / China NT Pharma
New P2 trial: A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease (clinicaltrials.gov) - Sep 4, 2021
P2, N=40, Not yet recruiting, Sponsor: Shanghai WD Pharmaceutical Co., Ltd.
- || levodopa/carbidopa ER (WD-1603) / China NT Pharma
New P1 trial: PK Study of WD-1603 in Healthy Subjects (clinicaltrials.gov) - Oct 18, 2020
P1, N=8, Recruiting, Sponsor: Hong Kong WD Pharmaceutical Co., Limited
- || dabigatran etexilate mesylate oral suspension (WD-1602) - Shanghai Fudan / Zhangjiang, China NT Pharma
New P1 trial: A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa (clinicaltrials.gov) - Oct 18, 2020
P1, N=20, Not yet recruiting, Sponsor: Hong Kong WD Pharmaceutical Co., Limited
- || levodopa/carbidopa ER (WD-1603) / China NT Pharma
New P1 trial: A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions (clinicaltrials.gov) - Sep 17, 2020
P1, N=8, Not yet recruiting, Sponsor: Hong Kong WD Pharmaceutical Co., Limited
- || levodopa/carbidopa ER (WD-1603) / China NT Pharma
New P1 trial: WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects (clinicaltrials.gov) - Aug 13, 2020
P1, N=8, Recruiting, Sponsor: Hong Kong WD Pharmaceutical Co., Limited
- || levodopa/carbidopa ER (WD-1603) / China NT Pharma
Trial completion, Trial primary completion date: WD-1603 PK Study in Healthy Volunteers (clinicaltrials.gov) - Feb 13, 2020
P1, N=8, Completed, Sponsor: Hong Kong WD Pharmaceutical Co., Limited
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | Trial primary completion date: Feb 2019 --> Sep 2019
- |||| PF708 (teriparatide biosimilar) / China NT Pharma, Pfenex
FDA event: Alvogen and Pfenex’ PF708 (biosimilar, teriparatide) Receives FDA’s Approval for the Treatment of Osteoporosis @alvogenpr @Pfenex https://t.co/8CBAeOpklg (Twitter) - Oct 7, 2019
- | levodopa/carbidopa ER (WD-1603) / China NT Pharma
New P1 trial: WD-1603 PK Study in Healthy Volunteers (clinicaltrials.gov) - Dec 3, 2018
P1, N=8, Not yet recruiting, Sponsor: Hong Kong WD Pharmaceutical Co., Limited
- ||||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Enrollment closed: A Comparison of PF708 and Forteo in Osteoporosis Patients (clinicaltrials.gov) - Aug 23, 2017
P3, N=168, Active, not recruiting, Sponsor: Pfenex, Inc
Not yet recruiting --> Completed | Trial primary completion date: Feb 2019 --> Sep 2019 Recruiting --> Active, not recruiting
- |||||||||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
New P3 trial: A Comparison of PF708 and Forteo in Osteoporosis Patients (clinicaltrials.gov) - Dec 22, 2016
P3, N=168, Recruiting, Sponsor: Pfenex, Inc
- ||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Trial completion: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - Aug 4, 2016
P1, N=70, Completed, Sponsor: Pfenex, Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Enrollment closed: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - May 4, 2016
P1, N=70, Active, not recruiting, Sponsor: Pfenex, Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
New P1 trial: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - Jan 15, 2016
P1, N=70, Recruiting, Sponsor: Pfenex, Inc